Key terms
About BWAY
Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BWAY news
Yesterday
8:57am ET
BrainsWay Boosts Deep TMS Presence in Israel
Yesterday
8:06am ET
Brainsway expands Deep TMS access in Israel
Apr 04
8:57am ET
BrainsWay’s Deep TMS Shows Promise for Parkinson’s
Apr 04
8:15am ET
Brainsway announces published review results on potential of Deep TMS
Mar 28
8:15am ET
Brainsway announces results in late-life depression post-marketing analysis
Mar 18
7:57am ET
BrainsWay Enhances Support for Military Mental Health
Mar 18
7:37am ET
Brainsway broadens partnership with Katie’s Way Plus
Mar 11
6:26am ET
Buy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion Potential
Mar 11
6:14am ET
Brainsway price target raised to $13 from $12 at H.C. Wainwright
Mar 07
9:31am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
Mar 06
7:34am ET
Brainsway reports Q4 EPS 0c vs 12c last year
No recent press releases are available for BWAY
BWAY Financials
Key terms
Ad Feedback
BWAY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BWAY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
